Compare XOMA & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XOMA | LXRX |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.0M | 703.3M |
| IPO Year | N/A | 2000 |
| Metric | XOMA | LXRX |
|---|---|---|
| Price | $42.15 | $2.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $52.50 | $4.15 |
| AVG Volume (30 Days) | 106.4K | ★ 2.3M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $24.59 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $22.29 | $0.80 |
| 52 Week High | $42.81 | $2.53 |
| Indicator | XOMA | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 74.41 |
| Support Level | $37.00 | $1.11 |
| Resistance Level | $42.25 | $2.53 |
| Average True Range (ATR) | 0.41 | 0.13 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 84.15 | 97.10 |
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.